Skip to main content

SQI Diagnostics Looks to Raise $3.7M in Private Placement

NEW YORK (GenomeWeb News) – SQI Diagnostics today announced a non-brokered private placement intended to raise C$3.76 million (US$3.72 million) in gross proceeds.

The Toronto-based microarray diagnostic firm said it plans to offer up to a little more than 5 million units at C$.75 per unit as part of the placement. Each unit will consist of one common share and one common share purchase warrant. Each warrant will entitle the holder to buy one common share at C$1.10 for up to two years after the date of issuance.

The private placement is anticipated to close on or about May 1, SQI said.

SQI plans to use net proceeds from the placement for product development and commercialization, as well as sales and marketing, and general working capital.

The cash-strapped firm is in the midst of a turnaround effort. In November it created a special committee to review strategic alternatives, including a possible merger or sale. In its recent first quarter results it reported C$3,000 in revenues, which followed a 2012 fourth quarter in which it reported no revenues.

As of Dec. 31, 2012, the company had C$2.0 million in cash and cash equivalents.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.